脑出血的外科治疗:新证据与观念转变
自发性脑出血是致残致死性最高的卒中类型,传统开颅手术未能改善长期预后。近期ENRICH、MIND、SWITCH三项随机对照试验采用不同手术方式和人群重新评估外科治疗。ENRICH采用贝叶斯自适应设计,显示早期微创旁束入路手术治疗脑叶和前基底节出血在180天功能预后方面优效,脑叶出血患者尤为明显,死亡率更低且安全性与内科治疗相当。MIND显示导管抽吸深部幕上脑出血虽能显著减少血肿,但180天功能独立无统计学显著改善。SWITCH因提前终止而把握度不足,提示大而深的脑出血行去骨瓣减压不清除血肿可能降低死亡率、6个月严重残疾或死亡有减少趋势,无额外不良事件。
要点
- ENRICH试验显示,早期微创旁束入路手术(MIPS)治疗脑叶和前基底节出血,180天功能预后优于内科治疗,脑叶出血患者尤为明显,死亡率更低且安全性与内科治疗相当。
- MIND试验显示,导管抽吸治疗深部幕上脑出血虽能显著减少血肿、手术可行且安全,但180天功能独立无统计学显著改善。
- SWITCH试验因提前终止而把握度不足,提示大而深脑出血行去骨瓣减压不清除血肿可能降低死亡率、6个月严重残疾或死亡有减少趋势,无额外不良事件,但许多存活者仍为中重度残疾。
- ENRICH与SWITCH共同挑战数十年来对脑出血外科治疗的悲观态度,提示向选择性、机制导向的手术干预转变:脑叶出血侧重微创入路,恶性深部出血侧重减压。
- 正在进行的全球研究有望进一步明确患者选择、手术时机和操作优化。
适用人群与场景
- ENRICH试验纳入脑叶和前基底节脑出血患者,接受早期微创旁束入路手术(MIPS)或内科治疗。
- MIND试验纳入深部幕上脑出血伴中到大血肿患者,随机接受微创清除或标准内科治疗。
- SWITCH试验纳入大而深的脑出血患者,研究去骨瓣减压不清除血肿。
处置流程与药物剂量
- ENRICH试验采用早期微创旁束入路手术(MIPS)治疗脑叶和前基底节脑出血,在经验丰富的中心对精心选择患者实施。
- MIND试验采用导管抽吸行微创清除治疗深部幕上脑出血。
- SWITCH试验采用去骨瓣减压不清除血肿治疗大而深的脑出血。
研究设计与关键结果
- ENRICH试验采用贝叶斯自适应设计,显示早期MIPS治疗脑叶和前基底节出血在180天功能预后方面优效,脑叶出血患者尤为明显,死亡率更低,安全性与内科治疗相当。
- MIND试验显示导管抽吸深部幕上脑出血虽实现显著血肿减少、手术可行且安全,但180天功能独立无统计学显著改善,可能与深部出血占优及干预时机可能欠佳有关。
- SWITCH试验因提前终止而把握度不足,提示去骨瓣减压不清除血肿可能降低死亡率、6个月严重残疾或死亡有减少趋势,无额外不良事件,但许多存活者仍为中重度残疾。
证据类型、等级与局限
- 证据类型:三项随机对照试验(ENRICH、MIND、SWITCH)。
- ENRICH采用贝叶斯自适应设计,提供当代首个证据表明早期影像引导微创血肿清除在精心选择患者中可转化为有意义的临床获益。
- MIND未显示180天功能独立有统计学显著改善。
- SWITCH因提前终止而把握度不足。
- 局限:MIND缺乏获益可能与深部出血占优及干预时机可能欠佳有关;SWITCH因提前终止而把握度不足,许多存活者仍为中重度残疾,结局解读复杂;原文未报告其他局限性。
对床旁实践的改变
- ENRICH提示对脑叶和前基底节脑出血,在经验丰富中心对精心选择患者可行早期微创旁束入路手术以改善180天功能预后。
- MIND提示导管抽吸治疗深部幕上脑出血虽能减少血肿且安全,但未显示180天功能独立获益。
- SWITCH提示对大而深脑出血行去骨瓣减压不清除血肿可能降低死亡率、6个月严重残疾或死亡有减少趋势,但把握度不足且许多存活者仍为中重度残疾,需个体化、以患者为中心的决策。
- 作者认为,ENRICH和SWITCH共同挑战对脑出血外科治疗的悲观态度, signaling向选择性、机制导向的手术干预转变:脑叶出血侧重微创入路,恶性深部出血侧重减压。
指南或共识出处
- ENRICH试验
- MIND试验
- SWITCH试验
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
Spontaneous intracerebral hemorrhage (ICH) remains the most devastating form of stroke, with limited evidence supporting surgical intervention. Traditional craniotomy has shown no clear benefit in improving long-term outcomes, largely due to procedural invasiveness, delayed timing, and heterogeneous patient selection. Recently, three randomized controlled trials, the ENRICH, MIND, and SWITCH studies, re-examined the surgical management of ICH using distinct approaches and patient populations. The ENRICH trial evaluated early minimally invasive parafascicular surgery (MIPS) for lobar and anterior basal ganglia hemorrhages. Using a Bayesian adaptive design, it demonstrated superior functional outcomes at 180 days, particularly among patients with lobar ICH, with lower mortality and comparable safety to medical therapy. This trial provided the first contemporary evidence that early, image-guided minimally invasive hematoma evacuation can translate into meaningful clinical benefit when applied to carefully selected patients in experienced centers. Conversely, the MIND trial investigated catheter-based aspiration for deep supratentorial ICH. The study enrolled patients with moderate-to-large hematomas who were randomized to minimally invasive evacuation versus standard medical management. Although the procedure achieved substantial clot reduction, demonstrating procedural feasibility and safety, it did not show a statistically significant improvement in functional independence at 180 days. The lack of benefit may be related to the predominance of deep hemorrhages, which are less amenable to surgical evacuation, as well as potentially suboptimal timing of intervention. Lastly, the SWITCH trial investigated decompressive craniectomy without hematoma evacuation for large, deep-seated ICH. Although underpowered due to premature termination, SWITCH suggested a possible reduction in mortality and a trend toward fewer patients with severe disability or death at 6 months, without excess adverse events. However, many survivors remained moderately to severely disabled, underscoring the complexity of outcome interpretation and the need for individualized, patient-centered decision-making.Together, the ENRICH and SWITCH trials collectively challenge decades of therapeutic pessimism in ICH, signaling a shift toward selective, mechanistically informed surgical intervention in ICH, one emphasizing minimally invasive access for lobar bleeds and decompression for malignant deep hemorrhages. Ongoing global studies are expected to further define patient selection, timing, and procedural refinement.
参考来源
- de Oliveira Manoel AL, Msheik A, Schuind S, et al. Surgery for intracerebral hemorrhage: new evidence and changing perspectives. Crit Care. 2025. PMID: 41327234. doi:10.1186/s13054-025-05763-3
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。